Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “H7N9 Influenza”

Showing 20 of 0 results

Large-scale testing (Phase 3)Study completedNCT01911754
What this trial is testing

Japanese Pediatric H5N1 Vaccine Study

Who this might be right for
Influenza
Alachua Government Services, Inc. 60
Early research (Phase 1)Study completedNCT00912496
What this trial is testing

Booster Trial to 07-0019 With A/Anhui/05 With and Without MF59

Who this might be right for
Influenza
National Institute of Allergy and Infectious Diseases (NIAID) 637
Testing effectiveness (Phase 2)Study completedNCT03497845
What this trial is testing

Assess the Safety & Immunogenicity of Prime-Boost Vaccination Strategies Using H5Nx Virus Vaccine Adjuvanted With AS03 or MF59

Who this might be right for
Influenza A Virus, H5N1 Subtype
Biomedical Advanced Research and Development Authority 720
Early research (Phase 1)WithdrawnNCT02177734
What this trial is testing

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine(s) GSK3277510A and GSK3277509A in Adults 18 to 60 Years of Age

Who this might be right for
Influenza
GlaxoSmithKline
Testing effectiveness (Phase 2)Study completedNCT02213354
What this trial is testing

H7N9 Mix and Match With MF59 in Healthy Elderly Persons

Who this might be right for
Avian Influenza
National Institute of Allergy and Infectious Diseases (NIAID) 479
Early research (Phase 1)Study completedNCT05397119
What this trial is testing

A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Pandemic Flu Vaccine in Healthy Adults

Who this might be right for
Influenza, Pandemic
BlueWillow Biologics 40
Early research (Phase 1)Study completedNCT00812019
What this trial is testing

Dose Ranging Study to Evaluate Immunogenicity and Safety of Adjuvanted or Non-adjuvanted Cell Culture-derived H5N1 Influenza Vaccine in Young Adults (18-40 Years Old)

Who this might be right for
Influenza
Seqirus 753
Early research (Phase 1)Study completedNCT02335164
What this trial is testing

Evaluate the Immunogenicity and Safety of a Pandemic Avian Influenza Vaccine in Adults

Who this might be right for
Influenza
Vaxine Pty Ltd 270
Early research (Phase 1)Study completedNCT01675284
What this trial is testing

A Phase I Study to Evaluate the Safety, Reactogenicity, and Humoral Immune Responses to an Inactivated H5N1 Influenza Vaccine

Who this might be right for
Bird FluAvian InfluenzaInfluenza A(H5N1)
Medigen Biotechnology Corporation 36
Testing effectiveness (Phase 2)Study completedNCT00439335
What this trial is testing

Higher Dose Intradermal H5 Vaccine

Who this might be right for
Influenza
National Institute of Allergy and Infectious Diseases (NIAID) 227
Early research (Phase 1)Study completedNCT02151344
What this trial is testing

Evaluating the Safety and Immune Response to a Live H7N9 Influenza Virus Vaccine Followed by an Inactivated H7N9 Influenza Virus Vaccine, Given at Varying Intervals

Who this might be right for
Influenza A Virus, H7N9 Subtype
National Institute of Allergy and Infectious Diseases (NIAID) 100
Testing effectiveness (Phase 2)Study completedNCT06382311
What this trial is testing

Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Against Pandemic H5N1 Influenza Virus in Healthy Younger and Older Adults

Who this might be right for
Influenza, Human
GlaxoSmithKline 991
Testing effectiveness (Phase 2)Study completedNCT02229357
What this trial is testing

Evaluation of Priming Effects by PLAI Vaccine on the Subsequent Response to Inactivated H5N1 Vaccine

Who this might be right for
Avian Influenza
Mahidol University 60
Early research (Phase 1)Study completedNCT02480101
What this trial is testing

Reactogenicity, Safety and Immunogenicity of a LAIV H7N9 Influenza Vaccine

Who this might be right for
Influenza
Research Institute of Influenza, Russia 40
Testing effectiveness (Phase 2)Study completedNCT02586792
What this trial is testing

H7N9 Boost in Healthy Adults

Who this might be right for
Influenza
National Institute of Allergy and Infectious Diseases (NIAID) 27
Early research (Phase 1)Study completedNCT02957656
What this trial is testing

Safety and Immunogenicity of Priming With Live Attenuated A/H7N9 Influenza Virus Vaccine Followed By Inactivated A/H7N9 Influenza Virus Vaccine With AS03 Adjuvant

Who this might be right for
Influenza A Virus, H7N9 Subtype
National Institute of Allergy and Infectious Diseases (NIAID) 53
Early research (Phase 1)Study completedNCT01317758
What this trial is testing

H5N1 Mix and Match With AS03

Who this might be right for
Influenza
National Institute of Allergy and Infectious Diseases (NIAID) 245
Early research (Phase 1)Study completedNCT01656356
What this trial is testing

Phase I Safety and Immunogenicity of Live Attenuated Influenza H5 Candidate Vaccine Strain A/17/Turkey/Turkey/05/133 (H5N2) in Healthy Thai Volunteers

Who this might be right for
Preventive Avian Flu
Mahidol University
Testing effectiveness (Phase 2)Study completedNCT00415129
What this trial is testing

Safety and Immunogenicity of an Intramuscular Pandemic Influenza Vaccine in Adults and the Elderly

Who this might be right for
InfluenzaOrthomyxoviridae Infections
Sanofi Pasteur, a Sanofi Company 600
Early research (Phase 1)Study completedNCT01657929
What this trial is testing

H5-VLP + GLA-AF Vaccine Trial in Healthy Adult Volunteers

Who this might be right for
Influenza A Subtype H5N1 Infection
Access to Advanced Health Institute (AAHI) 105
Next Page

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation